StockIQpro
NASDAQ:EDIT

Editas Medicine, Inc.

Track all markets on TradingView
Track all markets on TradingView

Editas Medicine, Inc.'s revenue grew 25.4% in fiscal 2025 to $40.5M while operating margin rose to −394.9%. Free cash flow was −$165.8M, −409.3% of revenue, and the diluted share count rose 7.8%.Summary generated from Editas Medicine, Inc.'s SEC filings. Latest annual report filed Mar 9, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$40.5M
Revenue growth+25.4%
Revenue, 5-yr CAGR−14.9%
Gross marginn/a
Operating margin−394.9%
Net margin−395.0%
ROICn/a
Return on equity−198.1%
Debt / equity2.15
Free cash flow−$165.8M
FCF margin−409.3%
Share count change+7.8%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue2620783241
Operating income−193−226−169−251−160
Net income−193−220−153−237−160
Free cash flow−172−181−137−219−166

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)